BACKGROUND:Rosiglitazone, a peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist, is used in the treatment of type 2 diabetes mellitus, and in vitro data has shown that it may have anti-platelet effects independent of its hypoglycemic effects. The aim of this study was to assess the effect of rosiglitazone on circulating platelet activity in patients without diabetes mellitus who had coronary artery disease. METHODS:Ninety-two patients with stable, documented coronary artery disease without diabetes mellitus were studied. Patients were randomized (double-blind) to receive placebo or rosiglitazone for 12 weeks. Circulating platelet activity was measured at baseline and after 12 weeks of therapy with whole blood flow cytometry to quantify platelet P-selectin expression. RESULTS: The percentage of P-selectin positive platelets was significantly reduced by rosiglitazone treatment compared with placebo (P =.04). In the rosiglitazone group, the percentage of P-selectin positive platelets (median with interquartile range) decreased from 0.1 % (0.05-0.24) to 0.05 % (0.01-0.15). Rosiglitazone treatment significantly reduced the insulin resistance index (HOMA-R) compared with placebo (P =.02). No significant correlation was observed between change in platelet activity and change in HOMA-R. CONCLUSIONS:Rosiglitazone significantly reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease. This effect appears to be independent of any insulin-sensitising effect.
RCT Entities:
BACKGROUND:Rosiglitazone, a peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist, is used in the treatment of type 2 diabetes mellitus, and in vitro data has shown that it may have anti-platelet effects independent of its hypoglycemic effects. The aim of this study was to assess the effect of rosiglitazone on circulating platelet activity in patients without diabetes mellitus who had coronary artery disease. METHODS: Ninety-two patients with stable, documented coronary artery disease without diabetes mellitus were studied. Patients were randomized (double-blind) to receive placebo or rosiglitazone for 12 weeks. Circulating platelet activity was measured at baseline and after 12 weeks of therapy with whole blood flow cytometry to quantify platelet P-selectin expression. RESULTS: The percentage of P-selectin positive platelets was significantly reduced by rosiglitazone treatment compared with placebo (P =.04). In the rosiglitazone group, the percentage of P-selectin positive platelets (median with interquartile range) decreased from 0.1 % (0.05-0.24) to 0.05 % (0.01-0.15). Rosiglitazone treatment significantly reduced the insulin resistance index (HOMA-R) compared with placebo (P =.02). No significant correlation was observed between change in platelet activity and change in HOMA-R. CONCLUSIONS:Rosiglitazone significantly reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease. This effect appears to be independent of any insulin-sensitising effect.
Authors: S L Spinelli; J J O'Brien; S Bancos; G M Lehmann; D L Springer; N Blumberg; C W Francis; M B Taubman; R P Phipps Journal: PPAR Res Date: 2008 Impact factor: 4.964
Authors: Amanda Croasdell; Parker F Duffney; Nina Kim; Shannon H Lacy; Patricia J Sime; Richard P Phipps Journal: PPAR Res Date: 2015-12-02 Impact factor: 4.964
Authors: Francisco A Monsalve; Radha D Pyarasani; Fernando Delgado-Lopez; Rodrigo Moore-Carrasco Journal: Mediators Inflamm Date: 2013-05-27 Impact factor: 4.711
Authors: Katie L Lannan; Julie Sahler; Nina Kim; Sherry L Spinelli; Sanjay B Maggirwar; Olivier Garraud; Fabrice Cognasse; Neil Blumberg; Richard P Phipps Journal: Front Immunol Date: 2015-02-13 Impact factor: 7.561